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Background: Insomnia is a common sleep disorder in patients with breast cancer and
studies show a higher frequency than in the general population but it appears to be
understudied and the treatment seems to be a neglected problem. There is a growing
body of evidence about the efficacy of cognitive behavioral therapy for insomnia (CBT-I)
in breast cancer survivors (BCS). The aim of this review is to examine the best available
scientific evidence related to CBT-I and insomnia in patients with breast cancer and to
assess the effect of CBT-I on their psychosocial functioning, sleep, quality of life, and
mood.
Methods: Empirical articles published in peer-reviewed journals from the earliest reports
available until August 2015 were considered. The research on PubMed generated 18
papers, three of which did not meet the inclusion criteria. Another paper was retrieved
by screening the reference list of the previously selected papers.
Results: A total of 16 studies were found that evaluated the effects of CBT-I in breast
cancer patients. CBT-I appears to be an effective therapy for insomnia in BCS, improving
mood, general and physical fatigue, and global and cognitive dimensions of quality of
life. CBT-I may also reduce menopausal symptoms, such as hot flushes and night sweat
problems, frequency of medicated nights, level of depression, and anxiety.
Conclusions: CBT-I seems to be an eligible intervention for improving sleep in BCS.
Improvements concerning insomnia and sleep quality are durable (usually up to 12
months) and statistically significant.
Keywords: breast cancer survivors, cognitive behavioral therapy for insomnia, health-related quality of life,
insomnia, mood, oncology, review
INTRODUCTION
Insomnia is defined by the International Classification of Sleep Disorders, third edition (American
Academy of Sleep Medicine, 2014) as “a persistent difficulty with sleep initiation, duration,
consolidation, or quality that occurs despite adequate opportunity and circumstances for sleep,
and results in some form of daytime impairment.”
Insomnia is characterized by subjective complaints about dissatisfaction with sleep quality
or duration, difficulty falling asleep at bedtime, waking up too early in the morning or in the
middle of the night, or non-restorative, or poor quality sleep. Insomnia also involves subjective
reports of daytime symptoms such as fatigue or low energy, difficulties with cognitive functions,
Aricò et al. CBT-I in BCS
for instance attention, concentration, and memory, and mood
disturbances including irritability and dysphoria, all of which
can produce functional impairment and are often the primary
concerns pushing patients to seek treatment.
Patients with the diagnosis of breast cancer report very
often insomnia (Ohayon, 2002). It has been estimated that
∼30–60% of breast cancer women experience insomnia and
the prevalence is higher than in non-cancer patients (Savard
et al., 2009; Palesh et al., 2010). Notwithstanding the wide
spread of the phenomenon in this population, insomnia is
largely understudied. It has a high prevalence in women
with breast cancer for several reasons, such as a general
increase in psychological distress after the cancer diagnosis
and disruption of sleep due to increased frequency and
severity of hot flushes caused by menopause, often induced
by the chemotherapy (Fiorentino et al., 2010). Insomnia
seems to be determined by predisposing, precipitating, and
perpetuating factors (Spielman et al., 1987; American Psychiatric
Association, 1994; Bastien et al., 2004). Predisposing factors
can be several such as gender, older age, hyperarousability
as a trait, personal or family history, mood or trait anxiety,
predisposition to rumination; precipitating factors consist of
diagnosis of cancer, severity of disease, cancer treatment
that alter the levels of inflammatory cytokines or disrupt
circadian rhythms or sleep-wake-cycles, side effects of cancer
treatment, menopausal symptoms including pain or fatigue, and
medications used to treat side effects such as corticosteroids.
Moreover, perpetuating behavioral factors such as long term
use of medications or use of inappropriate medications, and
maladaptive coping, i.e., inaccurate appraisal of sleep difficulties
and quality (American Psychiatric Association, 1994; Bastien
et al., 2004).
Cognitive behavioral therapy for insomnia (CBT-I) is a brief,
sleep-focused, multimodal intervention (Morin and Espie, 2003;
Edinger and Carney, 2008). CBT-I is considered to be the gold
standard treatment for primary and comorbid insomnia in young
and older adults (Morin and Benca, 2012). The most common
approach includes a behavioral component (stimulus control,
sleep restriction, relaxation) combined with a cognitive and an
educational component (sleep hygiene). Each of these therapies
can be used alone or in combination; however, the combined
approach is preferred because several dimensions of insomnia
can be addressed at the same time.
An increasing number of studies have supported the efficacy
of CBT-I in patients with cancer (Garland et al., 2014). Overall,
results have been quite consistent in showing that CBT-I is
associated not only with improved sleep but also with a reduction
of psychological distress and improved quality of life (QoL). This
paper reports a review of the literature on CBT-I in breast cancer
survivors (BCS) with the aim to assess the effects of CBT-I on
psychosocial, sleep, health-related QoL, and mood.
MATERIALS AND METHODS
Data for this review consisted of empirical articles published
in peer-reviewed journals from the earliest data available until
August 2015. An extensive computer-assisted literature search
was conducted using the PubMed database. Search terms
included Breast Cancer, Sleep and Sleep Psychotherapy terms
such as cognitive behavior therapy, cognitive behavioral therapy,
cognitive behavioral therapy. Searches were conducted using
all possible combinations of sleep and sleep psychotherapy
terms and breast cancer. Excluded from consideration were
non-English articles, book chapters, monographs, commentaries,
review articles, case studies, dissertations, abstracts, letters
to the editor, and any non data-analytic or non peer-
reviewed reports. However, in the case of review articles,
their reference list was used to find additional eligible
articles.
The research on PubMed “breast cancer” AND (“cognitive
behavior therapy” OR “cognitive behavioral therapy” OR
“cognitive behavioral therapy”) AND “sleep” generated 18
papers. They were filtered and three of them were excluded: a
review (Mustafa et al., 2013); a study (Mustian, 2013) where CBT-
I was not the first line treatment (yoga vs. unspecified standard
care treatment), and a paper about male patients with prostate
cancer (Yousaf et al., 2012).
The reference list of the retrieved articles was reviewed
and articles meeting the following criteria were included:
(a) the target population were women diagnosed with breast
cancer and insomnia, and (b) cognitive behavioral therapy
or behavior therapy tailored for insomnia was used as the
primary psychotherapy treatment. This screening produced one
additional article (Roscoe et al., 2015) that was added to the final
list which included 16 papers in total.
RESULTS
The studies investigating CBT-I in patients with breast cancer
identified for inclusion are listed in Table 1. All of these
studies were carried-out in non-metastatic cases (stages 0-III)
who had completed treatment for cancer at least 1 month
before. The sample size in the studies ranged from 10 to
242 and the majority (75%) used a randomized controlled
design. All of them specified treatment status (post radiation,
chemotherapy, surgery, life-time, or current hormone therapy),
with the exception of two reports: one described generic “post
primary treatment” (Dirksen and Epstein, 2008) and the other
did not specify it at all (Hunter et al., 2004). Nine studies did
not include objective measures because the authors used sleep
diaries, questionnaires, self-reported scales, or semi-structured
interview to evaluate sleep habits, sleep features, and complaints
about sleep. The remaining seven studies used objective measures
such as polysomnography (PSG; four reports) or actigraphy
(three papers). Individual CBT-I was delivered in only four
studies; in the majority of studies (nine) the treatment consisted
of group-administered sessions; finally, in three reports this
aspect was not specified. Almost in all of the studies, the
investigators enrolled patients with chronic insomnia judged to
be secondary to the neoplastic condition (insomnia started or
worsened significantly at the time of the diagnosis of breast
cancer).
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Studies Focused on the Effects of CBT-I on
Sleep
Most of the papers focused just on the effects of CBT-I on sleep.
In the first study, Quesnel et al. (2003) investigated the efficacy
of CBT-I in patients with BCS and chronic insomnia. This study
consisted of two phases. In the first phase, patients filled out
the sleep diary daily, in the second phase patients underwent
to group-administered CBT-I; PSG was recorded before and
after the treatment. The study included a follow-up period of 2
weeks after the end of the treatment. In order to evaluate the
maintenance of the therapeutic gains, additional evaluations were
carried-out 3 and 6 months later. The analysis of sleep diaries
showed a progressive reduction in Total Wake Time (TWT) and
a progressive increase in Sleep Efficiency (SE), following CBT-I.
The daily variation in sleep after treatment was much smaller
than at baseline and the therapeutic gains were generally well
maintained after treatment. Data from PSG confirmed the results
obtained by sleep diaries, highlighting a significant reduction of
TWT (after treatment and follow up at 3 and 6 months) and a
post-treatment increase in SE.
In order to determine the efficacy of CBT-I in BCS, Epstein
et al. (Epstein and Dirksen, 2007) performed a randomized
trial with women who completed primary cancer treatment.
The study procedure consisted of 2 consecutive weeks of pre-
treatment in which all participants completed daily sleep diaries
and wore a wrist actigraph each night. The women were
randomly assigned to a multicomponent intervention group
(stimulus control, sleep restriction therapy, sleep education,
and hygiene) or control group (sleep education and hygiene
alone). During the 2 weeks of the post-treatment phase, all
participants wore the wrist actigraph each night, completed
the daily sleep diaries and a questionnaire similar to the pre-
treatment instruments. Sleep diary data analysis revealed a
significant time effect on sleep-onset latency, Wake After Sleep
Onset (WASO), Total Sleep Time (TST), time in bed (TB),
sleep efficiency (SE), and sleep quality, indicating that both
groups improved after treatment. The sleep diary results showed
also that participants of the multicomponent intervention group
spent less time in bed than those of the control group after
treatment.
Tremblay et al. (2009) investigated the predictors of the
effect of CBT-I for chronic insomnia in BCS. The patients
were randomly assigned to CBT-I or waiting list. The
initial level of expectations and perceived credibility of the
treatment were the variables most consistently associated with
improvement of subjective sleep variables at post-treatment,
whereas improvement of subjective sleep was not associated with
PSG-assessed enhancements. At 6-month follow-up, subjectively
assessed sleep improvements were best predicted by adherence
to the behavioral strategies, but none of the predictors was
significantly associated with PSG assessed sleep improvements.
In another study (Fiorentino et al., 2010), the effects of
individual CBT-I on sleep were evaluated in a sample of
women with a history of breast cancer. The study considered
two conditions: treatment condition or delayed treatment
control condition. Objective measures of sleep were derived by
actigraphy, subjective data were obtained by compiling sleep
diaries daily. Self-rated insomnia was significantly improved in
the treatment group, when compared to the control group.
In a research on the feasibility of a self-help treatment for
insomnia associated with a neoplastic condition, Savard et al.
(2011) indicated that self-help CBT-I is a feasible intervention
in BCS. Indeed, self-reported adherence levels with specific
strategies for insomnia were very high and there was a
significant time effect on the Insomnia Severity Index (ISI)
total score and on all sleep variables derived from the sleep
diaries, QoL, and dysfunctional beliefs and attitudes about
sleep scores. Therapeutic effects were maintained at a 3-month
follow up.
In a recent study, Roscoe et al. (2015) wondered whether
providing breast cancer patients with the wakefulness-promoting
agent armodafinil would result in a greater adherence to CBT-
I instructions. Patients were randomly assigned to one of four
groups: CBT-I, armodafinil, CBT-I plus armodafinil, or no
treatment. Both the CBT-I+armodafinil and the CBT-I+placebo
groups had significantly greater post-intervention reductions in
insomnia severity than the placebo group. There were similar
improvements for sleep quality. Therapeutic gains on both
measures persisted 3 months later. CBT-I+ armodafinil was not
significantly different from CBT-I+placebo.
Studies Focused on the Effects of CBT-I on
Menopausal Symptoms
Hunter (Hunter et al., 2004) investigated the experience
of menopausal symptoms, the prevalence and treatment
preferences in a sample of women who had been prescribed
tamoxifen within the past 5 years. The participants completed
several questionnaires about types of treatment used to deal
with menopausal symptoms and treatment preferences. High
rates of symptoms were reported by patients. The majority of
women attributed their menopausal symptoms to tamoxifen.
Nevertheless, the adherence to treatment with tamoxifen
remained generally very high. Levels of depressed mood were
reported to be significantly higher than an equivalent non-
breast cancer, mid-aged sample. The experience of hot flushes
was not associated with depressed mood nor with global
health-related QoL. Anyway, the frequency of hot flushes was
associated with poorer emotional function, poorer body image,
anxiety and sleep problems. Patients, in general, expressed
a preference for non-hormonal treatments of menopausal
symptoms.
Dysfunctional sleep-related thoughts and sleep inhibitory
behaviors to the insomnia process were studied by Rumble
et al. (2010). Analyzing sleep diaries, nighttime pain, hot flushes,
dysfunctional sleep related thoughts and behaviors, fatigue and
mood, the authors found that poorer sleep was related to
nighttime pain and hot flushes. Dysfunctional sleep-related
thoughts and sleep inhibitory behaviors showed to be antecedents
of insomnia and higher levels of pain, fatigue and hot flushes;
while lower levels of positive mood and dysfunctional thoughts
seemed to be consequence of insomnia in this population.
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Mann et al. (2011) evaluated menopausal symptoms
following breast cancer treatment and the effect of CBT-I in a
randomized controlled trial. The participants had attended a
clinical interview, underwent a 24-h sternal skin conductance
monitoring and completed some questionnaire measuring
hot flushes and night sweats, mood, QoL, hot flush beliefs
and behaviors, optimism and somatic amplification. Women
were randomized to receive either usual care (access to clinic
support) or to usual care plus CBT-I. The data from sternal
skin conductance and questionnaires were collected also at 6–8
weeks post-treatment and, later at 6 months, participants filled
out questionnaires regarding the use of health services and
treatments, changes in lifestyle and health over the previous 4
months of treatment. Mann et al. (2011) also found that CBT-I
was significantly associated with a reduction in menopausal
symptoms (self-reported and physiologically measured) as well
as with a significant reduction in self-reported frequency, and
significant improvements in sleep quality and QoL.
In a subsequent investigation, Mann et al. (2012), using the
same study design, assessed menopausal symptoms at baseline, 9
and 26 weeks after randomization. The sample of women who
received CBT-I showed less frequently hot flushes and night
sweats than did those receiving usual care. These therapeutic
gains were maintained up to 26 weeks.
Studies Focused on the Effects of CBT-I on
the Immunologic System
A study by Savard et al. (2005a) aimed to assess immunological
effects of CBT-I for insomnia secondary to breast cancer.
The women were randomly assigned to CBT-I or waiting list.
Compared to the control group, women treated with CBT-I
showed higher secretion of interferon-γ and a lower increase
of lymphocytes at post treatment. Levels of interferon-γ and
interleukin-1β increased significantly after treatment. Significant
changes in white blood cells, lymphocytes and interferon-γ were
found at follow-up.
Studies Focused on the Effects of CBT-I on
Mood, Fatigue, and QoL
Dirksen et al. (Dirksen and Epstein, 2008) described the efficacy
of CBT-I on fatigue, mood, and QoL in a sample of women
who were at least 3 months post-completion of primary cancer
treatment. Women were randomly assigned to either the CBT-
I group, which received stimulus control instructions, sleep
restriction therapy, sleep education and hygiene, or the control
group which received sleep education and hygiene only. The
study protocol consisted of a 2-week pre-treatment period, a
6-week treatment period, and 2-week post-treatment period.
Participants in both treatment groups completed questionnaires
on fatigue, mood, and QoL at baseline. During the 2-week pre-
treatment period women completed daily sleep diaries and wore
a wrist actigraph each night. The subgroup receiving CBT-I had
significant improvements in fatigue, anxiety, depression, and
QoL. The control group who received only sleep education and
hygiene also had a statistically significant increase in QoL, with a
lower depression at post-treatment.
The efficacy of CBT-I on sleep but also psychological
and immunological aspects was studied by Savard et al. in
2005 (Savard et al., 2005b). Two experimental conditions
were considered: CBT-I and waiting list (control condition).
Follow-up evaluation was carried out 3, 6, and 12 months
after treatment. At pre-treatment the patients were invited to
complete several questionnaires (Insomnia Interview Schedule,
Structured Clinical Interview for the DSM IV, Insomnia Severity
Index, Sleep Diary, Hospital Anxiety and Depression Scale,
Multidimensional Fatigue Inventory, European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire) and to spend three consecutive nights in the
sleep lab. PSG was carried out also after treatment. Pooled
analyses showed a significant sleep improvement only in
the treated patients which were well maintained, and even
enhanced in some cases, up to 1 month after the end
of the intervention. Insomnia treatment was associated to
several other positive findings, including reduced use of sleep
medications, decreased anxiety and depression, and improved
global QoL.
A study by Matthews et al. (2012) aimed to assess the
adherence to CBT-I among BCS, following primary treatment.
Participants were randomly assigned to the CBT-I or the
placebo group (control condition). CBT-I was conducted
by individual weekly sessions. The CBT-I components used
were sleep restriction, sleep hygiene, stimulus control, and
cognitive therapy. Participants filled out sleep-wake diaries and
questionnaires about motivation, depression, anxiety, insomnia
and fatigue. During CBT-I patients showed a progressively
decreasing of adherence to the suggested rise time and time
in bed; on the contrary, the adherence to prescribed bedtime
remained constantly high. Lower fatigue and higher baseline
motivation seemed to be the factors associated with higher
adherence.
To date, the largest trial of CBT-I for insomnia in BCS has
been recently conducted by Savard et al. (2014) who reported
a significant improvement of all subjective sleep variables and
a large reduction of dysfunctional beliefs about sleep associated
with both professionally administered CBT-I (PCBT-I) and
video based CBT-I (VCBT-I). Although CBT-I was shown to be
associated to a significantly greater decrease than the control
condition of anxiety, depression, and fatigue scores, there were
no significant differences between VCBT-I and the no-treatment
condition (control) on these variables. CBT-I was associated with
a decrease of ISI score, early morning awakenings, depression,
fatigue, and dysfunctional beliefs about sleep. The remission
rate of insomnia showed to be significantly higher in CBT-I, as
compared to VCBT-I.
Matthews et al. (2014) examined the effect of CBT-I on sleep,
daytime symptoms, and QoL in BCS. The participants were
randomly assigned to CBT-I or behavioral placebo treatment.
CBT-I was associated with more improved sleep efficiency
and sleep latency than behavioral placebo treatment. This
improvement was sustained at follow up (3 and 6 months).
Participants after CBT-I showed to have less subjective insomnia,
better physical and cognitive functioning, positive sleep attitudes
and increased sleep hygiene knowledge.
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DISCUSSION
This survey reviewed the literature on CBT-I in women treated
for breast cancer and evaluated the efficacy of this intervention
on sleep, mood, and psychological outcomes.
All of the studies included reported a clear efficacy of CBT-I in
BCS. The efficacy covers several aspects including sleep, fatigue,
menopausal symptoms, mood, pain, QoL, and importantly,
immunological function. The improvements associated to CBT-
I were clinically and statistically significant for both subjective
(sleep dairies and questionnaires) and objective measures (PSG
and actigraphy). These results are in agreement with the
conclusions reported by Garland et al. (2014) in a systematic
review of CBT-I, in patients with different and heterogeneous
types of cancer (including breast cancer) and based on only 12
controlled and uncontrolled trials.
Insomnia associated with cancer is most likely multifaceted.
Although it is conceivable that other mechanisms are involved
(immune response, psychological reaction, personality, changes
in the circadian rhythms), the recent findings suggest a mediating
role for the somatic symptoms due to chemotherapy and
radiotherapy side effects, such as headache, nausea and digestive
symptoms, urination, and night sweats (Savard et al., 2015).
Several studies on cancer patients showed that chemotherapy
and radiotherapy were associated with worsening of insomnia
(Thomas et al., 2010; Palesh et al., 2012; Costa et al., 2014;
Savard et al., 2001). Chemotherapy seems to have an important
concurrent effect on sleep dysfunction, significantly mediated
by urinary symptoms, nausea, night sweats, digestive symptoms,
and dyspnea. The radiotherapy has a concurrent effect on
insomnia symptoms, significantlymediated by dyspnea and night
sweats (Savard et al., 2015).
All patients analyzed in the reports listed in the present review
completed the primary breast cancer treatment at least 1 month
before being studied; it is possible to hypothesize the existence
of a complex mechanism in which several elements take part,
worsening, and improving insomnia.
A recent study (Ratcliff et al., 2014) examined sleep before and
during chemotherapy for BCS and suggested that subjectively
disturbed sleep, during chemotherapy infusion, is associated with
greater fatigue, and more negative and anxious thoughts. It is
probable that improving sleep in these patients might improve
their mood and, consequently, QoL.
Psychological problems such as depression, anxiety and
intrusive thoughts were found to be common among breast
cancer patients. Jassim et al. (2015) reviewed the effects of
cognitive behavioral therapy on depression, anxiety, and mood
disturbances in 28 randomized controlled trials which included
a total of 3940 non-metastatic BCS. CBT was associated
with decreased levels of depression, anxiety, with concomitant
improvement in QoL, when compared to the control groups.
It is also important to notice that fatigue is one of the most
common symptoms of any neoplastic condition. Very often,
cancer-related fatigue is more severe and more enduring than
that of patients without cancer (Poulson, 2001). Although in
the majority of cases the etiology of fatigue is unknown and
the complex relationship between fatigue and sleep remains not
clearly established, behavioral, and psychosocial interventions
were shown to be efficacious to improving cancer-related fatigue.
This is important because, notwithstanding that fatigue is
a symptom common to many pathologies, in the particular
clinical picture of breast cancer comorbid with insomnia, it
can contribute to a mutual auto-reinforced relationship between
these two conditions.
Menopausal symptoms are very frequent in breast cancer and
can be due to biological aging, to hormone replacement therapy,
or to treatment (chemotherapy, ovarian ablation/suppression).
Menopausal symptoms have significant negative effects on sleep
and QoL. Effective non pharmacological treatment can represent
a therapeutic option for menopausal symptoms too. CBT in
BCS has also been reported to be effective in reducing the
impact of menopausal symptoms, such as hot flushes and
night sweats (Chilcot et al., 2014), independently from several
variables such as age, body mass index, time since breast
cancer diagnosis, menopausal status at time of diagnosis, or
cancer treatment (radiotherapy or chemotherapy or endocrine
treatment).
CBT-I was reported to have durable effects by most of the
studies (Quesnel et al., 2003; Savard et al., 2005a,b; Dirksen and
Epstein, 2008; Tremblay et al., 2009; Mann et al., 2011; Savard
et al., 2011; Mann et al., 2012; Roscoe et al., 2015; Savard et al.,
2005a,b), in agreement withMorin et al. (Morin and Benca, 2012)
who reported that CBT-I in chronic insomnia is usually followed
by a persistent therapeutic effect over time, whereas patients
taking only drugs tend to relapse after discontinuation.
CBT-I might trigger a virtuous cycle by improving sleep
quality which, in turn, might improvemood; mood improvement
could possibly be associated with better treatment adherence and
reduced intake of medication for sleep disorders, reduced anxiety
and, finally with better sleep.
The treatment of disturbed sleep in BCS is important because
it involves young women, without cognitive impairment, and
with a long-term life expectation, as in chronic insomnia not
related to cancer. Moreover, people with a history of cancer have
a greater risk for depression than healthy subjects (Reyes-Gibby
et al., 2006).
The main limitation of the present review is the notable
heterogeneity across the studies, in terms of CBT-I type
(individual CBT-I, group CBT-I, VCBT-I, PCBT-I).
Despite the simplicity and availability of self-reported sleep
questionnaires, daily sleep dairies, these methods can be affected
by bias, misperception, overestimation or tendency to minimize
the problem. Moreover, PSG remains the gold standard for the
assessment of sleep disorders, allowing to evaluate objectively
sleep architecture. Therefore, PSG should be preferred to
subjective sleep evaluations. Nevertheless, questionnaires have
been demonstrated to be a suitable clinical instrument. Following
the current standards for the diagnosis of insomnia (American
Academy of Sleep Medicine, 2014), PSG is not necessary but
provides important information and can exclude conditions that
might cause insomnia and not be perceived by the patients. In this
view, PSG should be recorded in order to exclude accurately other
sleep disturbances, such as restless legs syndrome or obstructive
sleep apnea.
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A rich research agenda may arise from the above-reviewed
concepts about CBT-I in persons already treated for breast
cancer and some guidelines could be suggested. More frequent
follow-ups should be scheduled; the majority of the studies
planned follow-ups to 12 months, but it would be interesting and
important to assess sleep for longer over time.
In order to have a more complete clinical profile of the
patients and to manage opportunely the treatment, a closer
collaboration between specialists in sleep and oncology is
desirable. Screening for sleep disturbances is advisable in
routine oncology practice, given the prevalence of insomnia
in cancer and its detrimental effects on the QoL of the
patients.
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